Skip to main content
. Author manuscript; available in PMC: 2017 Dec 1.
Published in final edited form as: Int Forum Allergy Rhinol. 2016 Aug 2;6(12):1273–1283. doi: 10.1002/alr.21826

TABLE 4.

Summary of leukotriene modifying drugs for CRS in AERD

Study Year Study Design LOE Subjects (n) Study Groups Treatment Protocol Primary clinical end-points Conclusion
Fischer AR et al.49 1994 Randomized controlled trial with internal crossover 2 AERD 8

  1. Zileuton;

  2. Placebo

 600mg zileuton four times daily × 1 week prior to ASA challenge

  1. Symptoms

 Zileuton is associated with improved nasal symptoms and decreased mast cell mediators following aspirin challenge.
Dahlén B et al.50 1998 Randomized controlled trial with internal crossover 2 AERD 40

  1. Zileuton;

  2. Placebo

 600mg zileuton four times daily × 6 weeks

  1. Symptoms;

  2. Nasal airflow

 Zileuton is associated with decreased nasal symptoms and increased nasal inspiratory airflow.
Schäper C et al.51 2011 Randomized controlled trial with internal crossover 2 AERD 12 ATA 12

  1. Montelukast;

  2. Placebo

 10mg montelukast daily × 6 weeks

  1. Symptoms;

  2. Nasal airflow;

  3. Endoscopy;

  4. Olfactometry;

  5. Nasal lavage

 Montelukast is associated with improved symptoms, nasal airflow and inflammation among CRSwNP patients regardless of aspirin tolerance.

AERD = aspirin exacerbated respiratory disease; ATA = aspirin tolerant asthma; CRS = chronic rhinosinusitis; CRSwNP = chronic rhinosinusitis with nasal polyposis; LOE = level of evidence